BioXcel Therapeutics Inc (BTAI) — Cash Flow-to-Debt Ratio
BioXcel Therapeutics Inc (BTAI) has a Cash Flow-to-Debt Ratio of -0.08x as of March 2026, meaning its operating cash flow of $-11.81 Million could theoretically repay 0% of its total liabilities ($139.57 Million) in one year. Explore BioXcel Therapeutics Inc cash flow conversion to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BioXcel Therapeutics Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for BioXcel Therapeutics Inc across 11 annual periods. Also explore BioXcel Therapeutics Inc (BTAI) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for BioXcel Therapeutics Inc (2015–2025)
Year-by-year debt coverage analysis for BioXcel Therapeutics Inc. For market capitalisation and broader financial context, see BioXcel Therapeutics Inc (BTAI) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.41x | $-57.62 Million | $140.38 Million | ▲ +25.1% |
| 2024 | -0.55x | $-72.03 Million | $131.44 Million | ▲ +54.0% |
| 2023 | -1.19x | $-155.01 Million | $130.21 Million | ▼ -13.5% |
| 2022 | -1.05x | $-135.34 Million | $129.08 Million | ▲ +77.3% |
| 2021 | -4.62x | $-82.15 Million | $17.77 Million | ▲ +7.8% |
| 2020 | -5.01x | $-66.35 Million | $13.24 Million | ▼ -74.5% |
| 2019 | -2.87x | $-27.28 Million | $9.50 Million | ▲ +0.9% |
| 2018 | -2.90x | $-13.51 Million | $4.66 Million | ▼ -208.5% |
| 2017 | -0.94x | $-2.20 Million | $2.34 Million | ▲ +76.0% |
| 2016 | -3.91x | $-1.29 Million | $331.00K | ▼ -144.3% |
| 2015 | -1.60x | $-280.00K | $175.00K | — |